Tang Capital Management LLC Increases Position in Evolus, Inc. (NASDAQ:EOLS)

Tang Capital Management LLC boosted its holdings in Evolus, Inc. (NASDAQ:EOLS) by 3.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,997,399 shares of the company’s stock after acquiring an additional 150,000 shares during the quarter. Evolus accounts for approximately 3.7% of Tang Capital Management LLC’s investment portfolio, making the stock its 4th biggest holding. Tang Capital Management LLC owned 0.08% of Evolus worth $55,171,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Nantahala Capital Management LLC lifted its position in Evolus by 10.8% in the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock valued at $34,557,000 after acquiring an additional 305,300 shares in the last quarter. Caligan Partners LP lifted its position in Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after acquiring an additional 498,900 shares in the last quarter. Millennium Management LLC lifted its position in Evolus by 29.1% in the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock valued at $15,107,000 after acquiring an additional 308,753 shares in the last quarter. Boothbay Fund Management LLC lifted its position in Evolus by 30.9% in the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock valued at $14,217,000 after acquiring an additional 304,065 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Evolus by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company’s stock worth $13,412,000 after buying an additional 3,969 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Insider Transactions at Evolus

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares in the company, valued at $418,057.17. This trade represents a 28.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now owns 508,619 shares of the company’s stock, valued at $6,306,875.60. This represents a 1.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,241 shares of company stock worth $1,048,666 in the last quarter. Insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

EOLS has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. Finally, BTIG Research initiated coverage on shares of Evolus in a research report on Thursday, April 17th. They set a “buy” rating and a $21.00 target price on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $23.75.

Evolus Trading Down 3.0%

Shares of EOLS stock opened at $9.70 on Friday. The company has a 50 day moving average of $11.32 and a 200-day moving average of $12.33. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82. The firm has a market cap of $625.42 million, a P/E ratio of -10.66 and a beta of 1.11.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.